PAH News Briefs

lab test

Pirfenidone Delays PAH Progression in Rodent Model

Pirfenidone improves pulmonary hemodynamics and vascular remodeling in a rat model of pulmonary arterial hypertension (PAH), a new study published in Pulmonary Circulation found. The study also found that the treatment decreased the cleavage of IL-1β and IL-18, which are products of the activation of NLRP3 inflammasome and play key roles downstream from NLRP3. The…

cardiac catheterization

Study Highlights Noninvasive Approaches to Managing PAH

For patients with stable, low-risk cases of pulmonary arterial hypertension (PAH), current noninvasive approaches to risk stratification and disease management may be useful and more feasible than invasive right heart catheterization (RHC), according to a new study published in Expert Review of Cardiovascular Therapy. The researchers discuss the most appropriate timing for RHC and when…

connective tissue

Study Supports Use of Immunosuppressive Therapy for CTD-PAH

Researchers reported that existing evidence supports the use of immunosuppressive therapeutics in connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH), especially in systemic lupus erythematosus-associated PAH (SLE-PAH), as published in the International Journal of Rheumatic Disease. PAH is primarily characterized by pulmonary vascular remodeling which increases pulmonary vascular resistance. The current thinking when it comes…

pregnant woman with nurse

Researchers Report Full-Term, Healthy Neonates in Women With PAH

Researchers reported 7 out of 9 successful pregnancies and deliveries in a cohort of women with pulmonary arterial hypertension (PAH), as published in the Australian and New Zealand Journal of Obstetrics and Gynaecology. They noted that regional neuraxial anesthesia facilitated the delivery process and improved the patient experience. “The aim of this retrospective review was…

cardiopulmonary system

Inhaled Seralutinib Effectively Treats Animal Models With Severe PAH

Inhaled seralutinib improved cardiopulmonary hemodynamics and inflammatory biomarkers, reduced N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels, and reversed remodeling of the pulmonary vasculature in 2 animal models of pulmonary arterial hypertension (PAH). The treatment was found to be more effective than imatinib. These results were published in the European Respiratory Journal. “We are excited to…

gastrointestinal stomach

Modified TNX-201 Formulation Limits Gastric Release in PAH

Tenax Therapeutics has announced that its modified formulation of imatinib mesylate, TNX-201, effectively preserves bioavailability while minimizing gastric release in pulmonary arterial hypertension (PAH). The pharmacokinetic results, announced via news release, showed that TNX-201 bioavailability significantly exceeded Tenax’s relative bioavailability threshold as compared with Gleevec® tablets as reference. “Since it has been established that oral…

Pulmonary hypertension illustration

Cardiovascular MRI May Detect Meaningful RV Volume Changes in PAH

Cardiovascular magnetic resonance imaging (CMR) may be useful in detecting clinically relevant changes in right ventricular (RV) volumes and function related to pulmonary arterial hypertension (PAH), according to a study published in Pulmonary Circulation. Targeted therapy has demonstrated a reduction in morbidity and mortality in patients with PAH. As RV dilatation may predict clinical worsening…

electronic health record

New Algorithm Identifies PAH From Medical Records

Researchers developed a machine learning algorithm using only claims-based features that could identify cases of pulmonary arterial hypertension (PAH) in electronic medical records and published their results in Respiratory Research.  They reported that their algorithm was able to identify PAH cases when deployed across entire electronic medical records and said that the demographic and clinical…

arterial wall

Rodatristat Ethyl Plus Ambrisentan Reduces Occlusions in PAH Model

Monotherapy with rodatristat ethyl reduces pulmonary vascular occlusions, according to results from a preclinical study in a rat model of pulmonary arterial hypertension (PAH). Treatment with a combination of rodatristat ethyl and ambrisentan, a type-A endothelin receptor antagonist, led to a synergistic benefit in reducing occlusions. They also reduced mean pulmonary arterial pressure. These results…

Next post in IPF Podcasts